Key facts
- Takeda has agreed to a deal with Insilico Medicine.
- The agreement allows Takeda to utilize Insilico's generative AI platform.
- The AI platform will be used for identifying potential new drugs.
Japanese pharmaceutical giant Takeda has entered into a collaboration with Hong Kong-based Insilico Medicine. The agreement will provide Takeda with access to Insilico's generative artificial intelligence platform, which is designed to aid in the identification of potential new drug candidates. This partnership highlights the growing trend of cross-border biotech licensing agreements leveraging AI technologies.